Skip to main content
Top
Published in: BMC Gastroenterology 1/2014

Open Access 01-12-2014 | Research article

Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis

Authors: Takeshi Seta, Yoshinori Noguchi, Satoru Shikata, Takeo Nakayama

Published in: BMC Gastroenterology | Issue 1/2014

Login to get access

Abstract

Background

The intravenous use of protease inhibitors in patients with acute pancreatitis is still controversial. The purpose of this study was to evaluate the effectiveness of protease inhibitors intravenously administered to prevent pancreatitis-associated complications.

Methods

We updated our previous meta-analysis with articles of randomized controlled trials published from January 1965 to March 2013 on the effectiveness of protease inhibitors for acute pancreatitis. A systematic search of PubMed, EMBASE, the Cochrane Library, and Japana Centra Revuo Medicina was conducted. In addition, Internet-based registries (ClinicalTrials.gov, controlled-trials.com, UMIN, JMACCT, and JAPIC) were used to search for on-going clinical trials. Furthermore, references of review articles and previously published meta-analyses were handsearched. The main outcome of interest was the overall mortality rate from acute pancreatitis.

Results

Seventeen trials were selected for analysis. Overall, protease inhibitors did not achieve a significant risk reduction in mortality (pooled risk difference [RD], -0.02; 95% Confidence Interval [CI], -0.05 to 0.01; number needed to treat [NNT], 74.8) with low heterogeneity. A subgroup analysis in moderate to severe pancreatitis (defined by control mortality rate [CMR] >0.10) did not show a significant effect of protease inhibitors to prevent death (pooled RD, -0.03; 95% CI, -0.07 to 0.01; NNT, 1603.9) with low heterogeneity. An additional subgroup analysis of two trials with CMR >0.20 (i.e., low quality) revealed a significant risk reduction.

Conclusion

The present meta-analysis re-confirmed that there is no solid evidence that supports the intravenous use of protease inhibitors to prevent death due to acute pancreatitis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Cavallini G, Frulloni L, Bassi C, Gabbrielli A, Castoldi L, Costamagna G, De Rai P, Di Carlo V, Falconi M, Pezzilli R, Uomo G, ProInf-AISP Study Group: Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Dig Liver Dis. 2004, 36: 205-211. 10.1016/j.dld.2003.11.027.CrossRefPubMed Cavallini G, Frulloni L, Bassi C, Gabbrielli A, Castoldi L, Costamagna G, De Rai P, Di Carlo V, Falconi M, Pezzilli R, Uomo G, ProInf-AISP Study Group: Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Dig Liver Dis. 2004, 36: 205-211. 10.1016/j.dld.2003.11.027.CrossRefPubMed
2.
go back to reference Banks PA, Freeman ML: Practice parameters Committee of the American college of gastroenterology. practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006, 101: 2379-2400. 10.1111/j.1572-0241.2006.00856.x.CrossRefPubMed Banks PA, Freeman ML: Practice parameters Committee of the American college of gastroenterology. practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006, 101: 2379-2400. 10.1111/j.1572-0241.2006.00856.x.CrossRefPubMed
3.
go back to reference Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA: Enteral versus parenteral nutrition for acute pancreatitis. Cochrane Database Syst Rev. 2010, 20: CD002837- Al-Omran M, Albalawi ZH, Tashkandi MF, Al-Ansary LA: Enteral versus parenteral nutrition for acute pancreatitis. Cochrane Database Syst Rev. 2010, 20: CD002837-
5.
go back to reference Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T: Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. Eur J Gastroenterol Hepatol. 2002, 14: 679-686. 10.1097/00042737-200206000-00014.CrossRefPubMed Morimoto T, Noguchi Y, Sakai T, Shimbo T, Fukui T: Acute pancreatitis and the role of histamine-2 receptor antagonists: a meta-analysis of randomized controlled trials of cimetidine. Eur J Gastroenterol Hepatol. 2002, 14: 679-686. 10.1097/00042737-200206000-00014.CrossRefPubMed
6.
go back to reference Takeda K, Matsuno S, Sunamura M, Kakugawa Y: Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996, 17: 394-398.CrossRef Takeda K, Matsuno S, Sunamura M, Kakugawa Y: Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis. Am J Surg. 1996, 17: 394-398.CrossRef
7.
go back to reference Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S: Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatol. 2001, 1: 668-673. 10.1159/000055879.CrossRef Takeda K, Yamauchi J, Shibuya K, Sunamura M, Mikami Y, Matsuno S: Benefit of continuous regional arterial infusion of protease inhibitor and antibiotic in the management of acute necrotizing pancreatitis. Pancreatol. 2001, 1: 668-673. 10.1159/000055879.CrossRef
8.
go back to reference Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, Soma K, Saigenji K: Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004, 28: 369-373. 10.1097/00006676-200405000-00003.CrossRefPubMed Imaizumi H, Kida M, Nishimaki H, Okuno J, Kataoka Y, Kida Y, Soma K, Saigenji K: Efficacy of continuous regional arterial infusion of a protease inhibitor and antibiotic for severe acute pancreatitis in patients admitted to an intensive care unit. Pancreas. 2004, 28: 369-373. 10.1097/00006676-200405000-00003.CrossRefPubMed
9.
go back to reference Piaścik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, Gabryelewicz A: The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010, 39: 863-867. 10.1097/MPA.0b013e3181d37239.CrossRefPubMed Piaścik M, Rydzewska G, Milewski J, Olszewski S, Furmanek M, Walecki J, Gabryelewicz A: The results of severe acute pancreatitis treatment with continuous regional arterial infusion of protease inhibitor and antibiotic: a randomized controlled study. Pancreas. 2010, 39: 863-867. 10.1097/MPA.0b013e3181d37239.CrossRefPubMed
10.
go back to reference Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T: Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol. 2004, 16: 1287-1293. 10.1097/00042737-200412000-00009.CrossRefPubMed Seta T, Noguchi Y, Shimada T, Shikata S, Fukui T: Treatment of acute pancreatitis with protease inhibitors: a meta-analysis. Eur J Gastroenterol Hepatol. 2004, 16: 1287-1293. 10.1097/00042737-200412000-00009.CrossRefPubMed
11.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151: 264-269. 10.7326/0003-4819-151-4-200908180-00135.CrossRefPubMed Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009, 151: 264-269. 10.7326/0003-4819-151-4-200908180-00135.CrossRefPubMed
17.
go back to reference Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.CrossRefPubMed Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.CrossRefPubMed
18.
go back to reference Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW, Atkins D, Meerpohl J, Schünemann HJ: GRADE guidelines: 4. Tating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011, 64: 407-415. 10.1016/j.jclinepi.2010.07.017.CrossRefPubMed Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW, Atkins D, Meerpohl J, Schünemann HJ: GRADE guidelines: 4. Tating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol. 2011, 64: 407-415. 10.1016/j.jclinepi.2010.07.017.CrossRefPubMed
19.
go back to reference Greenland S, Robins JM: Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985, 41: 55-68. 10.2307/2530643.CrossRefPubMed Greenland S, Robins JM: Estimation of a common effect parameter from sparse follow-up data. Biometrics. 1985, 41: 55-68. 10.2307/2530643.CrossRefPubMed
21.
22.
go back to reference Light RJ, Pilemer DB: Summing up: the science of reviewing research. 1984, Cambridge, MA: Harvard University Press Light RJ, Pilemer DB: Summing up: the science of reviewing research. 1984, Cambridge, MA: Harvard University Press
23.
go back to reference Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50: 1088-1101. 10.2307/2533446.CrossRefPubMed Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50: 1088-1101. 10.2307/2533446.CrossRefPubMed
24.
go back to reference Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315: 629-634. 10.1136/bmj.315.7109.629.CrossRefPubMedPubMedCentral
26.
go back to reference Stata/SE 11 for Windows. 2009, College Station, Texas: Stata Corporation Stata/SE 11 for Windows. 2009, College Station, Texas: Stata Corporation
27.
28.
go back to reference Ryall RJ: Discussion on acute pancreatitis with a report on a clinical trial of trasylol. Anglo Ger Med Rev. 1966, 3: 274-283.PubMed Ryall RJ: Discussion on acute pancreatitis with a report on a clinical trial of trasylol. Anglo Ger Med Rev. 1966, 3: 274-283.PubMed
29.
go back to reference Trapnell JE, Talbot CH, Capper WM: Trasylol in acute pancreatitis. Am J Dig Dis. 1967, 12: 409-412. 10.1007/BF02241945.CrossRefPubMed Trapnell JE, Talbot CH, Capper WM: Trasylol in acute pancreatitis. Am J Dig Dis. 1967, 12: 409-412. 10.1007/BF02241945.CrossRefPubMed
30.
go back to reference Baden H, Jordal K, Lund F, Zachariae F: A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir Scand Suppl. 1967, 378: 97-102.PubMed Baden H, Jordal K, Lund F, Zachariae F: A double-blind controlled clinical trial of Trasylol. Preliminary results in acute pancreatitis and in prophylaxis against postoperative pancreatitis. Acta Chir Scand Suppl. 1967, 378: 97-102.PubMed
31.
go back to reference Bachrach WH, Schild PD: A double-blind study of Trasylol in the treatment of pancreatitis. Ann N Y Acad Sci. 1968, 146: 580-592. 10.1111/j.1749-6632.1968.tb20316.x.CrossRefPubMed Bachrach WH, Schild PD: A double-blind study of Trasylol in the treatment of pancreatitis. Ann N Y Acad Sci. 1968, 146: 580-592. 10.1111/j.1749-6632.1968.tb20316.x.CrossRefPubMed
32.
go back to reference Möller C, Stjernvall L: Clinical trial with Trasylol against acute pancreatitis. Ann Chir Gynaecol Fenn. 1969, 58: 296-299.PubMed Möller C, Stjernvall L: Clinical trial with Trasylol against acute pancreatitis. Ann Chir Gynaecol Fenn. 1969, 58: 296-299.PubMed
33.
go back to reference Baden H, Jordal K, Lund F, Zachariae F: Prophylactic and curative action of Trasylol in pancreatitis. A double-blind trial. Scand J Gastroenterol. 1969, 4: 291-295.PubMed Baden H, Jordal K, Lund F, Zachariae F: Prophylactic and curative action of Trasylol in pancreatitis. A double-blind trial. Scand J Gastroenterol. 1969, 4: 291-295.PubMed
34.
go back to reference Trapnell JE, Rigby CC, Talbot CH, Duncan EH: A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974, 61: 177-182. 10.1002/bjs.1800610303.CrossRefPubMed Trapnell JE, Rigby CC, Talbot CH, Duncan EH: A controlled trial of Trasylol in the treatment of acute pancreatitis. Br J Surg. 1974, 61: 177-182. 10.1002/bjs.1800610303.CrossRefPubMed
35.
go back to reference Death from acute pancreatitis. M.R.C. multicentre trial of glucagon and aprotinin. Lancet. 1977, 2: 632-635. Death from acute pancreatitis. M.R.C. multicentre trial of glucagon and aprotinin. Lancet. 1977, 2: 632-635.
36.
go back to reference Gauthier A, Gillet M, Di Costanzo J, Camelot G, Maurin P, Sarles H: Controlled therapeutic trial of aprotinin and glucagon in acute pancreatitis. Gastroenterol Clin Biol. 1978, 2: 777-784.PubMed Gauthier A, Gillet M, Di Costanzo J, Camelot G, Maurin P, Sarles H: Controlled therapeutic trial of aprotinin and glucagon in acute pancreatitis. Gastroenterol Clin Biol. 1978, 2: 777-784.PubMed
37.
go back to reference Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, Blumgart LH: A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978, 65: 337-341. 10.1002/bjs.1800650514.CrossRefPubMed Imrie CW, Benjamin IS, Ferguson JC, McKay AJ, Mackenzie I, O'Neill J, Blumgart LH: A single-centre double-blind trial of Trasylol therapy in primary acute pancreatitis. Br J Surg. 1978, 65: 337-341. 10.1002/bjs.1800650514.CrossRefPubMed
38.
go back to reference Imrie CW: Medical treatment of acute pancreatitis. Gastroenterology. 1978, 75: 766-767.PubMed Imrie CW: Medical treatment of acute pancreatitis. Gastroenterology. 1978, 75: 766-767.PubMed
39.
go back to reference Kirsch A, Werner U, Heinze D: Proteinase inhibiting agents and glucagon in acute pancreatitis. Zentralbl Chir. 1978, 103: 291-303.PubMed Kirsch A, Werner U, Heinze D: Proteinase inhibiting agents and glucagon in acute pancreatitis. Zentralbl Chir. 1978, 103: 291-303.PubMed
40.
go back to reference Soergel KH: Medical treatment of acute pancreatitis: what is the evidence?. Gastroenterology. 1978, 74: 620-628.PubMed Soergel KH: Medical treatment of acute pancreatitis: what is the evidence?. Gastroenterology. 1978, 74: 620-628.PubMed
41.
go back to reference Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut. 1980, 21: 334-339. Morbidity of acute pancreatitis: the effect of aprotinin and glucagon. Gut. 1980, 21: 334-339.
42.
go back to reference Freise J, Melzer P, Schmidt FW, Horbach L: Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. Z Gastroenterol. 1986, 24: 200-211.PubMed Freise J, Melzer P, Schmidt FW, Horbach L: Gabexate mesilate in the treatment of acute pancreatitis. Results of a Hannover multicenter double-blind study with 50 patients. Z Gastroenterol. 1986, 24: 200-211.PubMed
43.
go back to reference Yang CY, Chang-Chien CS, Liaw YF: Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987, 2: 698-700. 10.1097/00006676-198711000-00013.CrossRefPubMed Yang CY, Chang-Chien CS, Liaw YF: Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas. 1987, 2: 698-700. 10.1097/00006676-198711000-00013.CrossRefPubMed
44.
go back to reference Goebell H: Multicenter double-blind study of gabexate mesilate (Foy) given intravenously in low dose in acute pancreatitis [Abstract]. Digestion. 1988, 40: 83- Goebell H: Multicenter double-blind study of gabexate mesilate (Foy) given intravenously in low dose in acute pancreatitis [Abstract]. Digestion. 1988, 40: 83-
45.
go back to reference Harada H, Miyake H, Ochi K, Tanaka J, Kimura I: Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol. 1991, 9: 75-79.PubMed Harada H, Miyake H, Ochi K, Tanaka J, Kimura I: Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol. 1991, 9: 75-79.PubMed
46.
go back to reference Valderrama R, Pérez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, Estruch J: Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992, 51: 65-70. 10.1159/000200877.CrossRefPubMed Valderrama R, Pérez-Mateo M, Navarro S, Vázquez N, Sanjosé L, Adrián MJ, Estruch J: Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion. 1992, 51: 65-70. 10.1159/000200877.CrossRefPubMed
47.
go back to reference Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K, Beger HG: Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993, 104: 1165-1170.CrossRefPubMed Büchler M, Malfertheiner P, Uhl W, Schölmerich J, Stöckmann F, Adler G, Gaus W, Rolle K, Beger HG: Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology. 1993, 104: 1165-1170.CrossRefPubMed
48.
go back to reference Cicardi M, Testoni P, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, Bagnolo F: Antiproteasic activity of C1 inhibitor. Therapeutic perspectives. Ann Ital Med Int. 1994, 9: 180-182.PubMed Cicardi M, Testoni P, Bergamaschini L, Guzzoni S, Cugno M, Buizza M, Bagnolo F: Antiproteasic activity of C1 inhibitor. Therapeutic perspectives. Ann Ital Med Int. 1994, 9: 180-182.PubMed
49.
go back to reference Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF: Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000, 47: 1147-1150.PubMed Chen HM, Chen JC, Hwang TL, Jan YY, Chen MF: Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology. 2000, 47: 1147-1150.PubMed
50.
go back to reference Pezzilli R, Miglioli M: Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group. Dig Liver Dis. 2001, 33: 49-57. 10.1016/S1590-8658(01)80135-3.CrossRefPubMed Pezzilli R, Miglioli M: Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group. Dig Liver Dis. 2001, 33: 49-57. 10.1016/S1590-8658(01)80135-3.CrossRefPubMed
51.
go back to reference Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting randomized controlled trials. The CONSORT statement. JAMA. 1996, 276: 637-639. 10.1001/jama.1996.03540080059030.CrossRefPubMed Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, Stroup DF: Improving the quality of reporting randomized controlled trials. The CONSORT statement. JAMA. 1996, 276: 637-639. 10.1001/jama.1996.03540080059030.CrossRefPubMed
52.
go back to reference Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Med J Aust. 2006, 185: 263-267.PubMed Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does the CONSORT checklist improve the quality of reports of randomized controlled trials? A systematic review. Med J Aust. 2006, 185: 263-267.PubMed
53.
go back to reference Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG: The quality of reports of randomized trials in 2000 and 2006: a comparative study of articles indexed by PubMed. BMJ. 2010, 340: c723-10.1136/bmj.c723.CrossRefPubMedPubMedCentral Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG: The quality of reports of randomized trials in 2000 and 2006: a comparative study of articles indexed by PubMed. BMJ. 2010, 340: c723-10.1136/bmj.c723.CrossRefPubMedPubMedCentral
54.
go back to reference Uetani K, Nakayama T, Ikai H, Yonemoto N, Moher D: Quality of reports on randomized controlled trials conducted in Japan: evaluation of adherence to the CONSORT statement. Inter Med. 2009, 48: 307-313. 10.2169/internalmedicine.48.1358.CrossRef Uetani K, Nakayama T, Ikai H, Yonemoto N, Moher D: Quality of reports on randomized controlled trials conducted in Japan: evaluation of adherence to the CONSORT statement. Inter Med. 2009, 48: 307-313. 10.2169/internalmedicine.48.1358.CrossRef
55.
go back to reference Shikata S, Nakayama T, Yamagishi H: Quality of surgical randomized controlled trials for acute cholecystitis: assessment based on CONSORT and additional check items. J Hepatobiliary Pancreat Surg. 2008, 15: 297-303. 10.1007/s00534-007-1268-8.CrossRefPubMed Shikata S, Nakayama T, Yamagishi H: Quality of surgical randomized controlled trials for acute cholecystitis: assessment based on CONSORT and additional check items. J Hepatobiliary Pancreat Surg. 2008, 15: 297-303. 10.1007/s00534-007-1268-8.CrossRefPubMed
56.
go back to reference Bradley EL: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993, 128: 586-590. 10.1001/archsurg.1993.01420170122019.CrossRefPubMed Bradley EL: A clinically based classification system for acute pancreatitis. Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga, September 11 through 13, 1992. Arch Surg. 1993, 128: 586-590. 10.1001/archsurg.1993.01420170122019.CrossRefPubMed
57.
go back to reference Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC: Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974, 139: 69-81.PubMed Ranson JH, Rifkind KM, Roses DF, Fink SD, Eng K, Spencer FC: Prognostic signs and the role of operative management in acute pancreatitis. Surg Gynecol Obstet. 1974, 139: 69-81.PubMed
58.
go back to reference Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of disease classification system. Crit Care Med. 1985, 13: 818-829. 10.1097/00003246-198510000-00009.CrossRefPubMed
Metadata
Title
Treatment of acute pancreatitis with protease inhibitors administered through intravenous infusion: an updated systematic review and meta-analysis
Authors
Takeshi Seta
Yoshinori Noguchi
Satoru Shikata
Takeo Nakayama
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2014
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-14-102

Other articles of this Issue 1/2014

BMC Gastroenterology 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.